- Home
- GIGM vs SNTI Comparison
GIGM vs SNTI Comparison
Compare GIGM & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | SNTI |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 53.6M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | GIGM | SNTI |
|---|---|---|
| Price | $1.48 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 5.3K | ★ 4.5M |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $1.38 | $1.14 |
| 52 Week High | $1.89 | $5.10 |
Technical Indicators
Market Signals| Indicator | GIGM | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 33.38 |
| Support Level | $1.44 | $1.15 |
| Resistance Level | $1.56 | $1.28 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 40.07 | 1.46 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.